Skip to main content

Syndicate contentprostate cancer

Study of neighborhoods points to modifiable factors, not race, in cancer disparities

While cities have shown considerable racial disparities in cancer survival, those racial disparities virtually disappear among smaller populations, such as neighborhoods within that city. The finding comes from a new analysis published in the May 15, 2009 issue of CANCER, a peer-reviewed journal of the American Cancer Society.

New drug shows promise in treating drug-resistant prostate cancer

A new therapy for metastatic prostate cancer has shown considerable promise in early clinical trials involving patients whose disease has become resistant to current drugs.

Gene fusion discovery may lead to improved prostate cancer test

NEW YORK (April 9, 2009) -- A newly discovered gene fusion is highly expressed in a subset of prostate cancers, according to a study by researchers at Weill Cornell Medical College. The findings, reported in the April 1 issue of Cancer Research, may lead to more accurate tests for prostate cancer.

New medications show promise in treating drug-resistant prostate cancer

A new therapy for metastatic prostate cancer has shown considerable promise in early clinical trials involving patients whose disease has become resistant to current drugs.

M. D. Anderson study finds pre-surgical stress management improves mood, quality of life

HOUSTON - Brief stress management sessions prior to and immediately after surgery may have both short- and long-term benefit for men undergoing a radical prostatectomy for early-stage prostate cancer, according to research from The University of Texas M. D. Anderson Cancer Center.

A potential new target for treatment of hormone refractory prostate cancer

A new study identifies a protein that modifies the androgen receptor (AR) and influences its ability to regulate target genes linked with the progression of prostate cancer.

A new approach to prostate cancer detection

On Friday 20 March, US researcher Dr. Chris Beecher from the University of Michigan gave a well attended lecture about sarcosine, an N-methyl derivative of the amino acid glycine, at the 24th Annual EAU Congress in Stockholm, Sweden. Dr Beecher is a colleague of lead author Dr. Arun Sreekumar.

Tips from the American Journal of Pathology

Tracking Acute Kidney Injury

Dr. Eisei Noiri and colleagues at the University of Tokyo, Japan identified a novel biomarker to monitor acute kidney injury. They present their data in the April 2009 issue of The American Journal of Pathology.

To fight drug addiction, UB researchers target the brain with nanoparticles

BUFFALO, N.Y. -- A precise, new nanotechnology treatment for drug addiction may be on the horizon as the result of research conducted at the University at Buffalo.

Castrate resistant prostate cancer: New therapeutic approaches

Today Dr. Martin Gleave of the Vancouver Prostate Centre in Canada gave a lecture about new approaches to treat castrate-resistant prostate cancer (CRCP) during the 24th Annual Congress of the European Association of Urology in Stockholm, Sweden.

SPCG-4 trial: Update on watchful waiting versus radical prostatectomy

Stockholm, 20 March - In 2005, the Scandinavian Prostate Cancer Group Study 4 (SPCG-4) reported that radical prostatectomy improved prostate cancer survival compared with watchful waiting after a median of 8.2 years of follow-up. At the 24th Annual EAU Congress in Stockholm, Sweden the results after 3 more years of follow-up were reported by Professor Lars Holmberg from Uppsala, Sweden.

PSA screening cuts deaths by 20 percent

Screening for prostate cancer can reduce deaths by 20%, according to the results of the European Randomized Study of Screening for Prostate Cancer (ERSPC) published online 1700 hours CET, today 18 March (NEJM, Online First*).

Selected men with low-risk prostate cancer have good clinical outcomes without immediate treatment

A multi-center study of prostate cancer patients appearing in today's Journal of Urology recommends that for some men diagnosed with low-risk prostate cancer, opting not to initially receive treatment can be safe if they are closely monitored.

Early results favorable for 5-day radiation treatment of early stage prostate cancer

Preliminary results show that a shortened course of radiation therapy for prostate cancer called stereotactic body radiation therapy (SBRT) provides good PSA response for early-stage prostate cancer and has the same side effects as other treatments, according to a March 15 study in the International Journal of Radiation Oncology*Biology*Physics, the official journal of the American Socie

Dr. Arun Sreekumar lectures on new candidate biomarker at Annual EAU Congress

Arnhem, 10 March 2009 -- The standard Prostate Specific Antigen (PSA) test for prostate cancer cannot tell the difference between aggressive and slow-growing forms. At the Annual EAU Congress, which will be held from 17 to 21 March 2009 in Stockholm (SE), Dr.



About us

Science Blog was started in August 2002. It lives, breathes and eats press releases from research organizations around the globe. Most of what you read here are press releases from the outfits named in the stories themselves. Got a news story you think belongs here? Let's talk. The other half of the equation is blog posts from readers like you. So if you have an interest in science, please register and join others like you in an ongoing, vibrant dialog about what makes the world tick. Meantime, please take a minute to read our Privacy Policy and Site Disclaimer.


Premium Drupal Themes by Adaptivethemes